Skip to Main Content

Paper Details

Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer.
Cancer Discov
81
2020
ER, ER+, HER, HER Kinase, HER kinase, HER2, HER2 mutations, HER2-Mutant Metastatic Breast Cancer, HER2-mutant metastatic breast cancer, HER3, breast cancer, estrogen, estrogen receptor, fulvestrant, metastatic breast cancers, neratinib, pan-, patients
Author NameAffiliation
Ingrid A MayerVanderbilt-Ingram Cancer Center
Rebecca Nagy
Melanie DujkaInc.
José BaselgaMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Funda Meric-BernstamThe University of Texas MD Anderson Cancer Center
  • 1 - 7

Datasets

Release 1.2